Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers

Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers

Lung cancer survivors are at risk of developing second primary cancers (SPCs). Although some risk factors for the development of SPCs have been addressed, their impacts have not been clarified. This study, based on Taiwan’s National Health Insurance Research Database (NHIRD), a nationwide database,...

Full description

Bibliographic Details
Main Authors: Wen-Ru Chou, Ben-Chang Shia, Yen-Chun Huang, Chieh-Wen Ho, Mingchih Chen
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Journal of Clinical Medicine
Subjects:
lung cancer
second primary cancers
risk factors
tyrosine kinase inhibitor
Online Access:https://www.mdpi.com/2077-0383/11/17/5222

Similar Items

Similar Items